Last reviewed · How we verify

NCT04151849

Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota

Completed Last updated 21 February 2023
What this trial tests

trial testing GLP-1 receptor agonist in Type 2 Diabetes in 23 participants. Completed in 23 January 2023.

Timeline
7 November 2019
Primary endpoint
23 January 2023
23 January 2023

Quick facts

Lead sponsorUniversity of Tartu
StatusCompleted
Study typeOBSERVATIONAL
Enrollment23
Start date7 November 2019
Primary completion23 January 2023
Estimated completion23 January 2023
Sites1 location across Estonia

Drugs / interventions tested

Conditions studied

Sponsor

University of Tartu

Who can join

18 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this observational study is to describe the effects of glucagon-like peptide-1 (GLP-1) receptor agonists and Sodium-Glucose Co-transporter 2 inhibitors ( SGLT-2 inhibitors) on adrenal function. Secondary endpoint is change in intestinal microbiota.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of GLP-1 receptor agonist

Trials testing the same drug.

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other University of Tartu trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04151849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing